RIGGS RORY B

CIK 00010168354 companiesSAN FRANCISCO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001016835

Recent Transactions

50 trades

Exercise of In-Money
Cibus, Inc.$CBUS
Class A Common Stock
2025-06-09$0.00/sh+4,000,000→ 14,533,307 total
Exercise of In-Money
Cibus, Inc.$CBUS
Pre-Funded Warrant (right to buy)
2025-06-09−4,000,000→ 0 total
Exercise of In-Money
Cibus, Inc.$CBUS
Pre-Funded Warrant (right to buy)
2025-06-09−50,000→ 0 total
Exercise of In-Money
Cibus, Inc.$CBUS
Class A Common Stock
2025-06-09$0.01/sh+50,000→ 14,583,307 total
Award
Cibus, Inc.$CBUS
Class A Common Stock
2025-06-05$1.75/sh+5,714,286→ 10,533,307 total
Award
Cibus, Inc.$CBUS
Stock Option (Right-to-Buy)
2025-05-22+39,301→ 39,301 total
Disposition to Issuer
Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
2025-04-02−20,000→ 0 total
Disposition to Issuer
Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
2025-04-02−20,000→ 0 total
Disposition to Issuer
Intra-Cellular Therapies, Inc.
Restricted Stock Units
2025-04-02−2,951→ 0 total
Disposition to Issuer
Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
2025-04-02−20,000→ 0 total
Disposition to Issuer
Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
2025-04-02−4,322→ 0 total
Disposition to Issuer
Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
2025-04-02−7,009→ 0 total
Disposition to Issuer
Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
2025-04-02−20,000→ 0 total
Disposition to Issuer
Intra-Cellular Therapies, Inc.
Common Stock
2025-04-02$132.00/sh−131,512→ 0 total
Disposition to Issuer
Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
2025-04-02−16,757→ 0 total
Award
Cibus, Inc.$CBUS
Common Warrant
2025-01-21+4,000,000→ 4,000,000 total
Award
Cibus, Inc.$CBUS
Pre-Funded Warrant
2025-01-21$2.50/sh+4,000,000→ 4,000,000 total
Conversion
Cibus, Inc.$CBUS
Class B Common Stock
2024-12-31−1,388,084→ 0 total
Conversion
Cibus, Inc.$CBUS
Class A Common Stock
2024-12-31+1,388,084→ 4,839,912 total
Award
Intra-Cellular Therapies, Inc.
Common Stock
2024-12-31$83.52/sh+215→ 131,512 total
Conversion
Cibus, Inc.$CBUS
Cibus Common Unit
2024-12-31−1,388,084→ 0 total
Award
Intra-Cellular Therapies, Inc.
Common Stock
2024-09-30$73.17/sh+246→ 117,108 total
Award
Cibus, Inc.$CBUS
Class A Common Stock
2024-09-18$4.00/sh+250,000→ 3,451,828 total
Award
Intra-Cellular Therapies, Inc.
Common Stock
2024-06-28$68.49/sh+262→ 116,862 total
Sale
Intra-Cellular Therapies, Inc.
Common Stock
2024-06-24$75.57/sh−4,462→ 116,600 total
Exercise/Conversion
Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
2024-06-24−20,000→ 0 total
Exercise/Conversion
Intra-Cellular Therapies, Inc.
Common Stock
2024-06-24$16.86/sh+20,000→ 121,062 total
Exercise/Conversion
Intra-Cellular Therapies, Inc.
Common Stock
2024-06-23+1,567→ 101,062 total
Exercise/Conversion
Intra-Cellular Therapies, Inc.
Restricted Stock Units
2024-06-23−1,567→ 0 total
Award
Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
2024-06-14+4,322→ 4,322 total
Award
Intra-Cellular Therapies, Inc.
Restricted Stock Units
2024-06-14+2,951→ 2,951 total
Award
Cibus, Inc.$CBUS
Class A Common Stock
2024-06-11$10.20/sh+98,040→ 3,201,828 total
Award
Cibus, Inc.$CBUS
Common Warrant
2024-06-11+98,040→ 98,040 total
Award
Intra-Cellular Therapies, Inc.
Common Stock
2024-03-31$69.20/sh+260→ 99,495 total
Exercise/Conversion
Intra-Cellular Therapies, Inc.
Stock Option (right to buy)
2024-03-20−20,000→ 0 total
Exercise/Conversion
Intra-Cellular Therapies, Inc.
Common Stock
2024-03-20$18.56/sh+20,000→ 99,235 total
Conversion
Royalty Pharma plc$RPRX
LP interests in RPI US Partners 2019, LP
2024-02-20−30,000→ 270,000 total
Conversion
Royalty Pharma plc$RPRX
Class A Ordinary Shares
2024-02-20+300,000→ 320,099 total
Sale
Royalty Pharma plc$RPRX
Class A Ordinary Shares
2024-01-04$27.55/sh−35,702→ 20,099 total
Sale
Royalty Pharma plc$RPRX
Class A Ordinary Shares
2024-01-03$27.79/sh−199,098→ 55,801 total
Sale
Royalty Pharma plc$RPRX
Class A Ordinary Shares
2024-01-02$28.52/sh−235,200→ 254,899 total
Award
Intra-Cellular Therapies, Inc.
Common Stock
2023-12-31$71.62/sh+251→ 79,235 total
Conversion
Cibus, Inc.$CBUS
Class A Common Stock
2023-12-29+1,500,000→ 3,103,788 total
Conversion
Cibus, Inc.$CBUS
Cibus Common Units
2023-12-29−1,500,000→ 1,367,193 total
Other
Cibus, Inc.$CBUS
Cibus Common Units
2023-12-29+1,505,967→ 2,867,193 total
Other
Cibus, Inc.$CBUS
Class B Common Stock
2023-12-29+1,505,967→ 2,867,193 total
Conversion
Cibus, Inc.$CBUS
Class B Common Stock
2023-12-29−1,500,000→ 1,367,193 total
Purchase
Cibus, Inc.$CBUS
Class A Common Stock
2023-12-12$10.58/sh+517,107→ 1,622,495 total
Other
Cibus, Inc.$CBUS
Pre-Funded Warrant
2023-12-12$10.57/sh+50,000→ 50,000 total
Conversion
Royalty Pharma plc$RPRX
LP interests in RPI US Partners 2019, LP
2023-11-13−47,559→ 300,000 total

Companies

Recent Filings

Address

C/O FIBROGEN, INC. 409 ILLINOIS ST.

SAN FRANCISCO, CA, 94158

View on SEC.gov